DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO
Retrieved on:
Tuesday, September 27, 2022
General Health, Other Health, Health, Pharmaceutical, Oncology, International economics, VP, EM, Doctor of Philosophy, Fred Hutchinson Cancer Research Center, Whitehead Institute, CEI, Brandeis University, Center, Research, CRISPR, Â, Innovation, Neoplasm, Phagocytosis, West Virginia University, Company, Senior, GSK, Macrophage, Industry, Therapy, University of Lille Nord de France, DRS, Head, Virginia University, History, Johns Hopkins School of Medicine, Amgen, AstraZeneca, Christophe, Drug development, Takeda, Harvard Medical School, Stanford University, Gilead Sciences, Genomics, R, DEM, Multimedia, University, SVP, Drug discovery, Management, Fine chemical, Vaccine, Immunology, Life
The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.
Key Points:
- The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.
- Mr. Grmusa, Dr. Quva and Dr. Francisco-Anderson join experienced industry leader John McCabe who serves as Chief Financial Officer and Chief Operating Officer.
- I am thrilled to join DEM Bio and to work alongside this world-class team of leaders in the emerging and highly promising field of innate immune system checkpoint inhibitors, said Mr. Grmusa.
- Mr. Grmusa brings 20 years of industry experience in business development, pharmaceutical portfolio management, R&D finance and financial planning and analysis.